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ABSTRACT
Background and aims Extended-release naltrexone (XR-NTX) is an under-used treatment option for opioid depen-
dence, today only available in a few countries in the world. Although effective, safe and feasible in short-term treatment,
long-term data are scarce and there is no recommendation for required treatment length. The aims of the study were to
determine the perceived need of long-termXR-NTX treatment and to examine long-term treatment outcomes.Design In
this prospective cohort study, following a parent 1-year study of XR-NTX, participants received treatment with XR-NTX at
their own discretion for a maximum of 104 weeks. Setting and participants Five urban, outpatient addiction clinics in
Norway, comprising opioid-dependent adults aged 18–60 years (n = 50) already participating in the parent study.
Intervention XR-NTX administered as intramuscular injections (380 mg) every 4 weeks. Measurements Time in
the study, use of opioids and other illicit substances, opioid craving and treatment satisfaction reported every 4 weeks.
Findings Among 58 participants who completed the 1-year parent study, 50 chose to continue the treatment with
XR-NTX. Median prolonged treatment time was 44.0 weeks [95% confidence interval (CI) = 25.5–62.5], ranging from
8 to 104 weeks. Most participants (35, 70%) reported no relapse to opioid use during treatment while a subgroup
(15, 30%) reported relapses to opioids during the study. Scores for mean treatment satisfaction and recommending treat-
ment to others were very high (>9) and mean opioid craving score was very low (<1) on a scale ranging from 0 to 10.
Conclusions Extended-release naltrexone (XR-NTX) was well tolerated in long-term treatment of opioid-dependent
individuals in Norway already in XR-NTX treatment. On average, the participants chose to continue treatment for almost
1 year beyond the initial 9–12months of treatment. Participants reported high treatment satisfaction and 70% showed no
relapse to opioids during the treatment period.
Keywords Antagonist treatment, extended-release naltrexone, long-term treatment, opioid use, recovery, treatment
duration, treatment of opioid dependence.
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INTRODUCTION
There are three classes of medication for treatment of opi-
oid dependence (ICD-10); full agonists, partial agonists
and antagonists [1]. While agonists have been used
world-wide for many years [2–5], long-acting injectable
versions of the opioid antagonist naltrexone is so far only
approved in the United States, Russia and Ukraine [6–9].
Administered as monthly intramuscular injections,
extended-release naltrexone (XR-NTX) blocks the euphoric
effects of opioids and offers a medication-assisted absti-
nence from opioids [10]. Studies have shown that
XR-NTX is an effective, safe and feasible treatment option
[8,11–17]. However, the majority of studies on XR-NTX
treatment have had limited time-frames and only a few
studies have reported results from 12 months or longer
© 2020 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.. Addiction
RESEARCH REPORT doi:10.1111/add.15378
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
[12,18,19]. To our knowledge, there are no recommenda-
tions regarding clinical treatment length with XR-NTX
based on research or national guidelines [20–22].
Opioid agonist maintenance treatment (OMT), which is
the current World Health Organization (WHO)-
recommended treatment for opioid dependence, is recom-
mended to be open-ended [23] and, at least in western
Europe, OMT has become a long-lasting or even life-long
treatment [4,24,25]. Opioid agonist treatment and
XR-NTX treatment differ in a number of ways [1]. While
opioid agonists maintain the opioid dependence, XR-NTX
blocks the effects of opioids and supports abstinence from
all opioids. Two randomized controlled trials suggested that
XR-NTX is equally as effective as the opioid agonist
buprenorphine–naloxone (BP-NLX) in short-term treat-
ment with regard to retention in treatment and reduction
in use of illicit opioids [26,27]. While studies of long-term
treatment outcomes for opioid dependence in general are
scarce, this is particularly applied to treatment with
XR-NTX [5,28,29]. The discrepancy between the some-
what limited duration of most clinical XR-NTX trials and
the often life-long, chronically relapsing duration of opioid
dependencies is striking [29].
Previous studies focusing on the patients’ motivation
for treatment showed that 50–80% of the participants
stated their main treatment goal to be long-term
abstinence from all opioids (including prescribed opioid
agonists) and other illicit substances [30–32]. XR-NTX
could be an adequate alternative for this group of
abstinence-motivated patients [5].
It has been postulated that longer duration of treat-
ment, in particular treatment lasting more than 2 years,
increases the likelihood of attaining patients’ treatment
goals [33]. An important key for an intervention to be ef-
fective is the users’ engagement and that treatment is facil-
itated according to the patients’ preferences, needs and
goals [34,35]. However, previous studies of XR-NTX have
not taken into account participants’ need or preference
for treatment duration [36]. According to the chronic na-
ture of opioid dependence, relapses are frequent and a
longer-term treatment period or subsequent treatment
episodes are often necessary before patients manage to
achieve their treatment goals [29]. Another aspect is that
abstinence achieved during a relatively short period of
treatment with XR-NTX seemed to wane after treatment
discontinuation, according to some cohort studies
[11,20,37]. Thus, there is a need to explore patients’
preferences on XR-NTX treatment duration.
The objectives of this study were to investigate the par-
ticipants’ perceived need and preference to remain in
XR-NTX treatment over time and to assess the efficacy of
long-term treatment. We aimed to explore (1) for how long
the participants chose to receive XR-NTX treatment, (2)
the use of opioids, other illicit substances and alcohol, (3)
opioid craving, (4) treatment satisfaction and participants’
willingness to recommend XR-NTX treatment to others




This prospective 2-year cohort study was a prolonged
follow-up to a previous 3-month randomized clinical trial
comparing XR-NTX with BP-NLX [26] and a subsequent
9-month follow-up study of XR-NTX [12,38–41]. At the
conclusion of the 9-month follow-up study, participants
were offered continued treatment with XR-NTX up to a pe-
riod of 104 weeks. The participants were free to discon-
tinue the XR-NTX treatment whenever they wanted
within the 2-year period. Participants who chose to discon-
tinue the treatment before maximum treatment time
(104 weeks) would not be re-enrolled into the study.
Participants and setting
Among the 58 participants who completed the parent
12-month study, 50 agreed to prolong the treatment
period with XR-NTX up to 104 weeks. Recruitment for
the parent study took place at outpatient clinics and
detoxification units at five urban hospitals in Norway.
Eligible patients were opioid-dependent (DSM-IV) adults
aged 18–60 years. Exclusion criteria were serious somatic
or psychiatric illness regarded as contraindications for
study participation, such as acute renal or hepatic failure,
severe cancer, psychosis or high risk of suicide. Women
could not be pregnant or lactating and agreed to use
effective birth control [12,26,39].
The study took place in a naturalistic outpatient setting
with clinical visits every fourth week. Participants had to
be enrolled into an OMT program prior to study inclusion
but did not receive any OMT medications during the study
participation. Enrolment in an OMT program ensured the
participants’ access to agonist treatment should they need
to after XR-NTX cessation. The first participant entered the
prolonged study in May 2014, and the last participant
completed the study in February 2018.
Study interventions
Participants received intramuscular injections with
extended-release naltrexone, 380 mg, once every fourth
week, in line with the medication regimen in the parent
study. Counselling was not mandatory, but participants
were offered psychosocial follow-up by clinicians according
to their individual needs and preferences.
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Measurements and outcomes
Every 4 weeks during their time in treatment, the partici-
pants reported substance use, opioid craving, treatment
satisfaction and recommendation of XR-NTX treatment to
others.We used the same inventories as in the parent study
[12,26,39], and only actual assessments were used in the
analyses. The primary outcome variable was time in
XR-NTX treatment, defined as the number of weeks partic-
ipants chose to receive XR-NTX injections. If they wanted
to end the treatment, they were asked about the reason
for this. Participants were not excluded if they relapsed to
opioid use or used other illicit substances while in the study.
Secondary outcome variables were use of opioids or
other illicit substances such as cannabis, amphetamines,
benzodiazepines and alcohol for intoxication within the
4 weeks preceding each interview. The assessment of sub-
stances was based on: 0 = no use; 1 = yes, on 1 or 2 days
in 4 weeks; 2 = yes, weekly; and 3 = yes, daily or almost
daily.
The degrees of opioid craving, satisfaction with treat-
ment and recommendation of treatment to others were
assessed using a validated visual analog scale (0–10).
Research ethics
The study was approved by the Regional Committee for
Medical and Health Research Ethics Southeast Norway,
the Norwegian Medicines Agency and the boards of
research ethics at the participating hospitals. Monitoring
of the studywas conducted by the publicly funded Regional
Monitoring Authorities, according to Good Clinical
Practice standards. Before inclusion in the parent study,
participants provided a written informed consent. The
treatment carried no cost for the participants. They were
not paid or compensated for taking part in the study, with
the exception of reimbursement of travel expenses for using
public transportation.
Statistical analyses
The analyses performed in this extension study were not
pre-registered and should be considered as exploratory. By
means of an exploratory approach, a growth mixture
model (GMM) was estimated to identify potential homoge-
neous subgroups of participants following distinct trajecto-
ries in opioid use. The number of groupswas determined by
applying the Bayesian information criterion, where the
smaller value means a better model, and requiring
reasonable group sizes, non-overlapping 95% confidence
intervals (CI) for trajectories and average within-group
probabilities of 0.80 or higher. Baseline characteristics of
the identified subgroups were compared by independent-
samples median test or χ2 test, as appropriate.
Time in treatment was assessed by a Kaplan–Meier
analysis, and subgroups with distinct trajectories identified
by GMMwere compared by log-rank test. The development
in the use of substances (four-category ordinal variables)
was assessed by generalized linear mixed models with fixed
effects for time, measured in weeks. Linear mixed models
with time as a fixed effect were estimated to assess the
development in continuous variables, opioid craving,
treatment satisfaction and treatment recommendation.
The time and time-squared were included into the models
where the development exhibited a non-linear pattern
(opioids, cannabis, amphetamines, alcohol, opioid craving
and treatment satisfaction and recommending XR-NTX).
If the non-linear part was negligible, only linear time was
entered the model (benzodiazepines). All models included
random effects for participants nested within the study
center. The regression models were estimated for the total
sample first and then stratified by subgroups identified by
GMM. For stratified analyses, the additional fixed effects
for subgroup as well as interaction between subgroup
and time were included. All models were adjusted for age
and sex. The results were presented graphically as either
odds for more use of certain substance or average value
with 95% confidence interval (CI). Results with P-values
below 0.05 were considered statistically significant. The
analyses were performed using SPSS software version 24
(IBM, Armonk, NY, USA), SAS statistical package version
9.4 (SAS Institute Inc., Cary, NC, USA) and Stata version
16 (StataCorp, College Station, TX, USA).
RESULTS
Of the 50 participants who chose to prolong treatment
with XR-NTX, 24 had been in XR-NTX treatment for
12 months and 26 for 9 months (Fig. 1). The mean age
was 36 years, and 82%were men. Patients’ characteristics
were representative of the full patient group enrolled into
the parent study [12,26,38,40,41].
The median time in this 2-year prolonged treatment
study was 44.0 weeks (95% CI = 25.5–62.5), ranging
from 8 to 104 weeks. Nearly half the participants contin-
ued treatment for more than 1 year, while 30% [15] and
54% [27] ended treatment after 24 weeks and 52 weeks,
respectively. At the end of the study (104 weeks), 18%
[9] were still in treatment.
The use of illicit opioids was very low throughout the
study. However, the growth mixture model identified two
subgroups of participants with distinct patterns of opioid
use. The average within-group probabilities were above
0.95 and 95% CI non-overlapping, indicating homoge-
neous groups. There were no differences between the
groups concerning which study medication the partici-
pants received in the parent randomized controlled trial
(RCT). In the ‘no-relapse’ group [35], 24 reported no opioid
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use at all, while 11 reported a few single days of use during
the study participation. In the ‘relapse’ group [15], partic-
ipants reported more frequently single days with use [6] or
daily/almost daily use over longer periods [9].
Participants in the no-relapse group had used other
illicit opioids significantly longer prior to study inclusion
(P = 0.023), but no other differences between the groups
in baseline characteristics were found (Table 1). The
median time in treatment did not differ between the groups
[48.0 weeks (95%CI = 24.8–71.2) in the no-relapse group
and 40.0 weeks (95% CI = 29.9–50.1) in the relapse
group, P = 0.345; see Fig. 2].
The proportional odds assumption was met for all sub-
stance use variables. Overall, there was a weak
non-significant linear trend (Fig. 3a) towards less use of
opioids throughout the study period (P = 0.085 and
0.045 for time components), with no differences in trend
between the groups. The odds for more use of opioids were,
however, significantly higher for the relapse group than the
no-relapse group throughout the study (P < 0.001)
(Fig. 3b).
Use of other illicit substances and alcohol is displayed in
Fig. 3c–j. There was a significant trend towards less use of
cannabis (Fig. 3c, P = 0.028 and P = 0.456 for time com-
ponents) and benzodiazepines (Fig. 3g, P < 0.001). The
odds for more use of benzodiazepines were significantly
higher in the opioid relapse group throughout the study
(P = 0.009) (Fig. 3h). However, the trend in use of benzo-
diazepines (Fig. 3h) showed a more pronounced reduction
in odds for use in the relapse group than in the no-relapse
group (P = 0.039).
Alcohol use showed no significant trend during the
study period (Fig. 3i). However, participants in the
no-relapse group exhibited stable and somewhat decreas-
ing odds for more use of alcohol, while participants in the
relapse group increased their alcohol use at first, but then
rapidly decreased it to essentially no use towards the end
of the study period. These differences were significant
(Fig. 3j, P = 0.030 and P = 0.015 for first- and second-or-
der interactions).
Opioid craving scores remained low during the study,
with a mean score <1 on a scale ranging from 0 to 10
(Fig. 4a).
The scores for treatment satisfaction and
recommending XR-NTX to other opioid-dependent individ-
uals remained very high throughout the study, with mean
scores>9 and>9.5 respectively, on a scale ranging from 0
to 10 (Fig. 4b,c).
When asked why they wanted to discontinue the
XR-NTX treatment before 104 weeks, 29 participants
Figure 1 Study flow-chart
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stated that they felt strong enough to stay abstinent with-
out XR-NTX, four expressed a desire to get high, three
reported that they were tired of being in treatment, five
were reported as dropouts and we have missing data on
the last nine participants.
XR-NTX was well tolerated, and only five participants
reported transient adverse events: sleep disturbance, gas-
trointestinal discomfort and different types of infections.
None of the adverse events were considered as serious or
related to the study medication and none led to discontin-
uation of the study medication or ending of the study. No
serious adverse events were reported among the partici-
pants during the first 3 months after study completion.
DISCUSSION
In this 2-year prolonged follow-up to a previous 1-year
study of XR-NTX, the participating opioid-dependent indi-
viduals chose to continue XR-NTX treatment for median
44 weeks. Opioid use was low during the study. Only 15
participants were identified as a relapse group, while 35
were identified as a no-relapse group. Use of other illicit
substances and alcohol was also low during the study.
Throughout the study, participants reported low craving
scores and high treatment satisfaction and they would, to
a high degree, recommend XR-NTX to others. When asked
why they wanted to discontinue XR-NTX, the majority of
participants stated that they felt strong enough to stay ab-
stinent without XR-NTX. Only a few non-serious adverse
events were reported during the study.
To our knowledge, this is the first study reporting
outcomes from long-term treatment with XR-NTX up to
3 years, and the first study focusing on the participants’
preferences regarding treatment length.
The average treatment length in our study, 44 weeks in
addition to the previous 36 or 48 weeks in the parent
study, corresponds well to previous findings on treatment
trajectories across various treatment modalities, indicating
that opioid-dependent individuals are more likely to
Table 1 Life-time and baseline characteristics of all participants and stratified by subgroups identified by growth mixture model.
Life-time characteristics
No-relapse group (n = 35) Relapse group (n = 15)
Mean (SD), n (%) Median (min–max) Mean (SD), n (%) Median (min–max)
Age, mean (SD) 35.4 (8.8) 33 (22–60) 37.3 (9.5) 37 (22–51)
Women, n (% of total study sample) 4 (8) 5 (10)
Hepatitis C seropositive, n (% of total in the group) 13 (37.1) 10 (66.7)
Injecting users, n (% of total in the group) 28 (80) 14 (93.3)
Injecting use, age at onset, mean (SD) 22.8 (7.4) 20 (14–45) 23.0 (7.8) 19 (14–34)
Years of injecting use, mean (SD) 8.5 (9.3) 5 (0–40) 12.1 (11.6) 8 (0–35)
Substance use, age at onset, mean (SD)
Heroin 24.0 (7.5) 21 (15–43) 21.8 (5.6) 22 (13–33)
Other illicit opioids 23.7 (8.3) 23.5 (8–41) 25.7 (10.2) 26 (14–46)
Cannabis 14.7 (3.1) 14 (10–27) 14.8 (2.3) 14 (12–20)
Amphetamines 17.7 (4.6) 17 (11–35) 17.9 (4.2) 18 (14–30)
Benzodiazepines 20.5 (7.5) 19 (10–45) 20.3 (6.9) 17 (14–35)
Alcohol for intoxication 13.1 (2.6) 13 (6–17) 14.7 (2.8) 14 (12–23)
Years of substance use, mean (SD)
Heroin 6.8 (5.7) 5 (0–27) 6.8 (4.0) 6 (0–14)
Other illicit opioidsa 3.4 (7.1) 0.5 (0–32) 0.8 (2.1) 0 (0–7)
Cannabis 11.2 (7.9) 11 (0–33) 12.2 (9.2) 13 (0–28)
Amphetamines 6.2 (6.5) 4.5 (0–27) 8.1 (8.4) 5 (0–28)
Benzodiazepines 5.9 (8.7) 3 (0–37) 3.5 (2.5) 4 (0–10)
Alcohol for intoxication 5.8 (6.4) 4 (0–23) 2.2 (3.2) 1 (0–10)
a
P = 0.023 for independent-samples median test. SD = standard deviation.
Figure 2 Time in treatment with extended-release naltrexone. Num-
ber at baseline was 50, declining to 9 at week 104.
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succeed with their treatment goal when the treatment
duration is at least 2 years [33].
Time in treatment did not differ between the identified
two subgroups of participants. This finding indicates that
preferred treatment time is not necessarily related to
whether or not a patient used opioids but may rather be re-
lated to other aspects, such as the participants’ treatment
goal.Wewould emphasize that relapse to opioid use should
not be an exclusion criterion for long-term XR-NTX treat-
ment in clinical practice.
Opioid dependence is a chronic and relapsing disease,
and it is reasonable that treatment shouldmatch these fea-
tures. OMT is often regarded as a life-long treatment, while
XR-NTX has been mainly used for limited time-periods.
Length of XR-NTX treatment should be tailored according
to the individuals’ needs and preferences [21], and not re-
stricted due to administrative time limitations. Insurance
policies, high cost and lack of policy priority has been
identified as administrative hindrances for the utilization
of XR-NTX [42,43]. The participants in our study received
XR-NTX free of cost, were not excluded from the study if
they relapsed to opioid use or used other illicit substances
and they could discontinue the treatment at their own
discretion within the 2-year period. Few restrictions and
high treatment satisfaction increased the likelihood of
Figure 3 Odds for substance use among study participants. Odds for more substance use among all participants (left), and odds for more substance
use in no-relapse group and relapse group 2 (right) with 95% confidence interval. Number at baseline was 50, declining to 9 at week 104.
Figure 4 Opioid craving score, treatment satisfaction and recommen-
dation of treatment. Visual analog scales were used to assess: (a) heroin
craving (0–10, with 0 indicating none and 10, very strong), (b) treatment
satisfaction (0–10, with 0 indicating low and 10, very high) and (c) rec-
ommendation of treatment to others (0–10, with 0 indicating not at
all and 10, very much so). Figures display mean and 95% confidence in-
terval. At baseline, craving score was reported by 47 participants and 50
reported treatment satisfaction and recommendation of treatment,
numbers declining towards 9 at week 104.
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treatment duration being correlated with participants’
needs and preferences.
Our study suggests that many abstinence-motivated
opioid-dependent individuals need and prefer longer-term
treatment with XR-NTX to be prepared for post-treatment
abstinence from opioids. The majority of participants stated
that they felt strong enough to stay abstinent from opioids
without XR-NTX as the reason for discontinuing the treat-
ment. Missing data on this variable is a limitation of the
study; however, the available data suggest that treatment
discontinuation correlated with the participants’ readiness
to stay abstinent from opioids.
Similar to the findings in the parent study [12,26], par-
ticipants reported low use of opioids, other illicit substances
and alcohol. Craving scores were low, and they reported
high scores on treatment satisfaction and on recommenda-
tion of XR-NTX to others. These findings also confirm
XR-NTX as an effective and feasible option in long-term
treatment. The participants’ willingness to recommend
XR-NTX treatment to other opioid-dependent individuals
underscores the fact that the participants themselves per-
ceived XR-NTX to be an effective treatment option, even
if they relapsed to opioid use.
The safety and efficacy of short-term treatment with
XR-NTX is well documented [8,11,12,18,26,27], but
documentation on long-term treatment is lacking. In our
study we found a very high tolerability, with very few and
transient non-serious adverse effects, and none of the
participants terminated treatment due to tolerability
issues. Our data suggest that XR-NTX is also safe and well
tolerated in long-term treatment.
The patients’ characteristics corresponded well with
the total sample of the parent study [12,26]. When
entering the parent study, a limited number of participants
were already in recovery in OMT and not using illicit sub-
stances, while a majority reported ongoing illicit substance
use and serious addiction-related problems [38]. While
opioid-dependent individuals already in recovery in OMT
may need XR-NTX in a shorter transition phase to obtain
medication-free abstinence over time, those who have an
ongoing opioid addiction and addiction-related problems
are likely to need longer-term treatment.
Participants’ abstinence from or use of opioids identi-
fied early in the study was very likely to be maintained
throughout their study period. The relatively low number
of participants in the study may have prevented us from
identifying groups with clear changes in patterns of opioid
use, as seen in other studies [36,44,45]. However, the fact
that a number of participants continued their opioid use
during the study emphasizes the importance of XR-NTX
treatment being reinforced by psychosocial interventions
[17,46–48], as recommended for OMT [23,49]. The par-
ticipants who used opioids chose to continue XR-NTX
treatment, although they could have received agonist
treatment if they wanted to. These participants may have
had a treatment goal other than abstinence, more in line
with a harm reduction approach and a controlled use of
opioids. This finding may be useful in clinical practice,
meaning that XR-NTX could attract opioid users with dif-
ferent kinds of motivation, and clinicians should be atten-
tive to the pattern of opioid use early in the treatment
process and tailor the treatment strategy accordingly
concerning treatment length and content. Some partici-
pants clearly expressed an unmet need for psychosocial
follow-up, and we suggest that this lack of follow-up is
the reason behind some of the treatment dropouts. How-
ever, we did not systematically record whether or not the
participants needed or received psychosocial follow-up
during the study. This is a limitation of the study, as psy-
chosocial approaches may reinforce the process of
recovery.
The lack of urine drug testing (UDT) is another limita-
tion of the study, as participants’ reports of substance use
could not be confirmed. In the parent study, however, the
UDTs corresponded well with the information provided by
the participants [12,26].
Study participants who decided to end treatment with
XR-NTX before 104 weeks were not allowed to re-start
treatment. Thus, this study does not reflect a real-life clin-
ical setting where patients may choose to stop the medica-
tion, regret their decision and be allowed to re-start the
medication [36]. Some participants regretted ending
XR-NTX treatment before the end of the study, and re-
quested re-inclusion in the study. However, re-inclusion
was not a part of the study design, and thus participants
who relapsed to opioid use were recommended to consider
initiating agonist treatment in OMT. Opioid users in general
are often in need of several treatment episodes before
achieving long-term abstinence [29]. It is therefore impor-
tant that clinical practice facilitate a possible re-start on
XR-NTX for those who express this need.
Further research should investigate post-treatment
efficacy and patients’ willingness to re-start XR-NTX treat-
ment after discontinuation, as induction of XR-NTX is
challenging [27]. It is also important to explore factors that
enable or prevent opioid users from achieving recovery and
to maintain abstinence from opioids after treatment dis-
continuation. Increased knowledge of such factors may
guide clinicians to tailor individual treatment trajectories
in a more effective way.
CONCLUSIONS
Extended-release naltrexone seems to be effective, well
tolerated and feasible in long-term treatment up to 3 years.
Clinicians should be attentive to patients’ needs and
preferences and XR-NTX treatment should be individually
tailored with regard to duration and content.
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Trial registration
Clinicaltrials.gov no. NCT01717963, first registered: 28
October 2012. Protocol version no. 3C, 12 June 2012.
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